Physician dispensing continues to be a significant cost driver for workers’ comp, and regulators continue to launch efforts to combat the associated high costs, including recent initiatives in Pennsylvania, Idaho, and Hawaii.
Physician dispensing – the practice of physicians directly dispensing medications to patients without the use of a pharmacy – is often marketed as convenient, but by bypassing pharmacy review safeguards, it can lead to issues of safety, efficacy, and higher costs. This is especially the case when certain physician dispensers choose to prescribe higher-cost medications in unusual doses, strengths, or formulations, when equally effective and more affordable variations are available.
The trends driving physician dispensing have shifted multiple times over the years, and regulators have continued to update rules to help combat the associated inflated costs. While regulatory change can take time, many states in the last several months have made efforts to push forward initiatives for change.
On October 19th, the Idaho Advisory Committee on Workers’ Compensation held a special subcommittee meeting to discuss ongoing concerns with physician-dispensed medication. Despite reimbursement limits adopted in 2025, physician dispensing still comes with high costs, and the subcommittee is now considering whether additional measures may be needed to strengthen existing cost controls, making this an issue to watch for potential changes to reimbursement and utilization controls.
Meeting participants reported prices for physician-dispensed medications, including creams and patches, substantially above pharmacy alternatives. Additionally, stakeholders noted a pattern of continued dispensing despite issues such as injured workers reporting nonuse or lack of benefit, duplicate therapies, and insufficient medical necessity documentation.
Utilization patterns were described as a “whack-a-mole” challenge, with changes in drug strengths or formulations potentially placing high-cost products outside the existing therapeutic-equivalent reimbursement cap. Participants reported concerns involving a small number of prescribers and requested provider input to better understand the issue.
On October 21st, the Pennsylvania Workers’ Compensation Advisory Council met to discuss legislative developments and other system updates, including a review of the 2025 Physician Dispensing Report. The report noted that physician-dispensed drugs made up 5% of total drug payments in 2025, an increase from 4% in 2024.
Additionally, the five leading drugs by prescription-related payments were diclofenac sodium, Zylotrol, lidocaine, pregabalin, and cyclobenzaprine HCL, many of which are frequently seen in physician dispensing, prompting regulators to continue to focus on physician dispensing in the near future.
In August, the Alaska Workers’ Compensation Board’s Medical Services Review Committee (MSRC) advanced a proposed 2027 medical fee schedule that would establish new reimbursement limits and billing requirements for physician-dispensed, repackaged, topical, over-the-counter (OTC), and compounded drugs.
The committee completed its fourth and final review of proposed revisions to the 2027 Medical Fee Schedule and presented their recommendations to the Workers’ Compensation Board for approval. The draft proposal was accepted with minor revisions, but additional rulemaking procedures are still underway. At this time, the draft proposal states that all drugs dispensed by a physician must be reimbursed at the manufacturer’s AWP using the original NDC.
August also saw Florida finalize a physician dispensing rule change by updating administrative code 69L-7.730 | Health Care Provider Medical Billing and Reporting Responsibilities. This change aligned physician dispensing rules with a court ruling made earlier this year in the case of Publix Super Markets, Inc. et al. v. Department of Financial Services (Case No. 1D2023 0941), which established that injured workers’ statutory right to choose where they obtain prescription medications applies only to pharmacies and pharmacists – not to physicians who dispense drugs directly from their offices.
In essence, the ruling found that carriers may deny authorization or reimbursement for physician dispensed medications without violating section 440.13(3)(j), even where the medication is otherwise medically necessary and appropriate. However, this decision does not prohibit physician dispensing, nor does it change the statutory reimbursement rates when a physician dispensed drug is otherwise authorized.
And at the beginning of the year, Georgia House Bill 1119 was introduced, which would have restructured how prescription drugs are prescribed, dispensed, and reimbursed in the state’s workers' comp system. While the bill did not advance, it featured significant changes to physician dispensing rules, requiring documentation of medical necessity, prior authorization, and more. For ongoing coverage of the latest legislation and policy updates impacting workers' comp, visit the Healthesystems Advocacy & Compliance page for our weekly Regulatory Recap.





